Using circular RNA hsa_circ_0000190 as a new biomarker in the diagnosis of gastric cancer

Chen, Shijun; Li, Tianwen; Zhao, Qiqi; Xiao, Bingxiu; Guo, Junming

doi:10.1016/j.cca.2017.01.025

Cited by 324 publications

(253 citation statements)

References 32 publications

Supporting

Mentioning

245

Contrasting

Order By: Relevance

“…A further 21 articles were excluded following more detailed assessment of the full text. Finally, 10 eligible studies (12 tests) were included in the meta-analysis (18)(19)(20)(21)(22)(23)(24)(25)(26)(27).…”

Section: Resultsmentioning

confidence: 99%

“…The characteristics of the 10 eligible studies are summarized in Table I ( [18][19][20][21][22][23][24][25][26][27]. A total of 799 patients with different cancer types and adjacent controls were involved in these 12 tests.…”

Section: Resultsmentioning

confidence: 99%

“…Highly conserved sequences and a high degree of stability in mammalian cells are two of their most important properties (10,13); thus, circRNAs have the potential to be ideal biomarkers in the diagnosis of cancer. Numerous studies have evaluated the performance of circRNAs in cancer diagnosis (18)(19)(20)(21)(22)(23)(24)(25)(26)(27); however, no systematic evaluation of circRNAs has been performed. The differences in the performances were too large and hence, to the best of our knowledge, the present study is the first meta-analysis to provide precise and controlled data on the diagnostic performance of circRNAs in cancer.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Circular RNA as a biomarker for cancer: A systematic meta‑analysis

Zeng

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Abstract. Circular RNAs (circRNAs) may serve as biomarkers for a potentially non-invasive diagnosis of cancer. To understand their diagnostic performance, a systematic meta-analysis of the published literature was conducted to review the diagnostic efficiency of circRNAs in patients with cancer. Eligible studies published up to November 30, 2017, on PubMed and EMBASE, were selected for the meta-analysis. All studies were carefully and independently reviewed by two researchers based on their titles and abstracts, following which full texts were perused for potential eligibility. All statistical analyses were performed by STATA 13.0 statistical software and Meta-DiSc 1.4. A total of 10 eligible studies were included. The pooled diagnostic odds ratio was 7.265. The pooled sensitivity was 0.708 and the pooled specificity was 0.722. The positive likelihood and negative likelihood ratios were 2.483 and 0.372, respectively. The area under the curve was 0.793. circRNA was determined to be a notably effective assistant diagnostic biomarker for cancer. IntroductionCancer is a major public health problem globally. Cancer is a class of diseases that undergoes uncontrollable cell proliferation and differentiation. Based on the 2015 cancer statistics, it is currently the second leading cause of mortality in numerous countries (including China, Europe and the USA), and is expected to surpass heart diseases as the leading cause of mortality in the near future (1). Although the risk of succumbing to cancer has decreased by ~20% from its maximum in 1991-2011 (1), it must be diagnosed with high sensitivity and specificity in order to determine the appropriate therapy and prognosis. Recently, a number of biomarkers with diagnostic and prognostic potential value have been demonstrated in numerous cancer types, including the tumor markers human epididymis secretory protein 4 and cancer antigen 125 in endometrial (2) and ovarian cancer types (3). Additionally, mutant genes have been used in the selection of an appropriate therapy, including epidermal growth factor receptor mutation in non-small cell lung cancer (4), Kirsten rat sarcoma viral oncogene homolog in colorectal cancer (5) and v-raf murine sarcoma viral oncogene homolog B1 mutation in melanoma (6); however, reliable and convenient biomarkers are required to evaluate the diagnostic and prognostic significance of different cancer types.Classic biomarkers present with potentially limiting factors, including cost, availability and reproducibility (7). Utility is compromised by different disease heterogeneities, specific genetics and proteomics, and the influence of lifestyle; therefore, a number of serum or tissue biomarkers, including non-coding RNAs (ncRNAs), have been developed for clinical experiments. ncRNAs have notable potential for future biomarker approaches. Numerous studies have reported the use of ncRNAs, including microRNAs and long ncRNAs (lncRNAs), in the early detection and prognosis of various cancer types (8,9). Previously, a number of studies focused on a nove...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Circular RNA as a biomarker for cancer: A systematic meta‑analysis

Zeng

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Almost all of the investigated circRNAs were down-regulated in digestive system malignancies, whereas the expression level of hsa_circ_0005075 was increased in HCC [31]. The specimen source of most studies was from a tissue sample, and only one study combined the use of tissue and plasma samples to examine the diagnostic accuracy of hsa_circ_0000190 in GC [32]. The sample size of the studies ranged from 62 to 259, with a median of 192.…”

Section: Resultsmentioning

confidence: 99%

A Meta-Analysis of the Diagnostic Accuracy of Circular RNAs in Digestive System Malignancy

Chen¹,

Zhang²,

Han³

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Circular RNAs (circRNAs), a novel class of noncoding RNAs, have been found to be dysregulated in various cancers. However, the clinical application value of these circRNAs in digestive system cancers remains to be clarified. We aimed to comprehensively explore the potential role of circRNAs as diagnostic indicators in digestive system malignancies. Methods: Relevant studies were systematically retrieved from PubMed, Web of Science and the Cochrane Library. The data that were required to complete 2 × 2 contingency tables were obtained from the included studies. Stratified analyses by cancer type, sample size and publication year were performed. Results: Thirteen studies with 2,276 individuals were included in the meta-analysis. The pooled sensitivity and specificity of circRNAs in the diagnosis of digestive system malignancy were 0.72 [95% confidence interval (CI): 0.65-0.77] and 0.77 (95% CI: 0.72-0.81), respectively. The overall positive likelihood ratio was 3.09 (95% CI: 2.64-3.62), and the overall negative likelihood ratio was 0.37 (95% CI: 0.31-0.44). The pooled diagnostic odds ratio was 8.38 (95% CI: 6.86-10.25), and the overall area under the curve was 0.81 (95% CI: 0.77-0.84), indicating good discriminative ability of circRNAs as biomarkers for digestive system malignancy. Conclusion: circRNAs distinguish patients with digestive system cancer from controls with relatively high diagnostic accuracy. circRNAs may be used as potential biomarkers for the diagnosis of digestive system malignancy.

show abstract

“…Chen S et al found hsa_circ_0000190 was down-expressed in gastric cancer plasma and were significantly correlated with tumor diameter, lymphatic metastasis, distal metastasis, TNM stage, and CA19-9 levels. These results suggest that hsa_circ_0000190 may be a novel noninvasive biomarker for the diagnosis of gastric cancer with a better sensitivity and specificity than commonly used biomarkers [37]. Taken together, circRNA paints a beautiful blueprint for the research of gastric cancer and further studies are required to explore their potential as biomarkers for GC as well as their pathologic role.…”

Section: Correlation Of Circrnas To Gastric Cancermentioning

confidence: 99%

Landscape of Circular RNAs in the Clinical Application of Digestive System Neoplasm

Zhou¹,

Fu²,

Hu³

et al. 2018

Chemotherapy

View full text Add to dashboard Cite

It has been confirmed that noncoding RNAs (ncRNAs) play an important role in cellular development, differentiation, proliferation and apoptosis of various carcinomas. As a member of the ncRNAs family, circular RNAs (circRNAs) are getting new research hotspots because of their newly discovered and numerous potential functions such as acting as microRNA (miRNA) sponges and binding to RNA-binding proteins (RBPs) to modulate the gene transcription. Herein, we review the current understanding of the roles of circRNAs in the clinical application of digestive system neoplasm and provide a new insight into the potential implications in the diagnosis and targeted therapy of digestive system carcinomas.

show abstract

Using circular RNA hsa_circ_0000190 as a new biomarker in the diagnosis of gastric cancer

Cited by 324 publications

References 32 publications

Circular RNA as a biomarker for cancer: A systematic meta‑analysis

Circular RNA as a biomarker for cancer: A systematic meta‑analysis

A Meta-Analysis of the Diagnostic Accuracy of Circular RNAs in Digestive System Malignancy

Landscape of Circular RNAs in the Clinical Application of Digestive System Neoplasm

Contact Info

Product

Resources

About